Phosphorus-containing thyromimetics

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7829552
APP PUB NO 20090118236A1
SERIAL NO

10580134

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
METABASIS THERAPEUTICS, INC.SAN DIEGO, CA47

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Boyer, Serge H San Diego, US 15 179
Erion, Mark D Del Mar, US 63 1327
Jiang, Hongjian San Diego, US 9 36

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (3)
2003/0040,535 Tetrazole compounds as thyroid receptor ligands 7 2002
2003/0114,521 Oxamic acids and derivatives as thyroid receptor ligands 2 2002
2005/0054,727 Phenyl naphthol ligands for thyroid hormone receptor 2 2004
 
NOVARTIS CORPORATION (3)
5401772 Heteroacetic acid derivatives 32 1993
5569674 Heteroacetic acid derivatives 27 1994
5654468 Heteroacetic acid derivatives 19 1996
 
SYNTEX (U.S.A.) INC. (1)
5284971 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents 34 1992
 
Shire LLC (1)
2004/0152,783 Controlled absorption of admixed thyroid hormone formulations 2 2003
 
NOVARTIS AG (2)
6117873 Substituted aminoalkane phosphonic acids 11 1999
6689896 Thyromimetic organic compounds 2 2001
 
NICHOLAS BACHYNSKY, M.D., P.A., TX (1)
4673691 Human weight loss inducing method 12 1984
 
ABBVIE DEUTSCHLAND GMBH & CO. KG (1)
5753254 Therapeutic agents containing thyroid hormones 36 1996
 
NORWEST BANK, ARIZONA, NATIONAL ASSOCIATION (1)
5951989 Method for the treatment of dry skin 52 1997
 
NEW RIVER PHARMACEUTICALS INC. (1)
2004/0116,391 Stabilized thyroxine compounds 5 2003
 
Dr. Karl Thomae GmbH (1)
5232946 Phenylethanolamines, their use as pharmaceuticals and as performance enhancers in animals 15 1990
 
SMITHKLINE BEECHAM P.L.C. (1)
5741803 Substituted thiazolidinedionle derivatives 20 1995
 
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (1)
6852706 Methods and compositions for healing heart wounds 8 2001
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (1)
6361992 Thyroid stimulating hormone superagonists 27 1998
 
PFIZER INC. (5)
6194454 Cyano containing oxamic acids and derivatives as thyroid receptor ligands 44 2000
6326398 Oxamic acids and derivatives as thyroid receptor ligands 9 2000
6620830 Thyroid receptor ligands 8 2001
6545018 Oxamic acids and derivatives as thyroid receptor ligands 6 2001
6723744 Indole carboxylic acids as thyroid receptor ligands 6 2002
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (1)
6982348 Aminoethanol derivatives 16 2002
 
CIBA-GEIGY CORPORATION (1)
4554290 Oxamic acid derivatives 11 1984
 
Hoechst Aktiengesellschaft (1)
5627173 Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders 2 1996
 
PFIZER PRODUCTS INC. (4)
6344481 Thyromimetic antiobesity agents 6 2000
6787652 6-Azauracil derivatives as thyroid receptor ligands 8 2000
6441015 Tetrazole compounds as thyroid receptor ligands 6 2001
6664291 Malonamic acids and derivatives thereof as thyroid receptor ligands 5 2001
 
THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (1)
6716877 Method to treat chronic heart failure and/or elevated cholesterol levels 3 2003
 
APPLIED BIOSYSTEMS, LLC (1)
2004/0029,187 Systems and methods for detection of nuclear receptor function using reporter enzyme mutant complementation 2 2003
 
JOSLIN DIABETES CENTER, INC. (1)
6468755 Method for identifying compounds for treatment of insulin resistance 2 2000
 
AMERLITE DIAGNOSTICS LIMITED (1)
4426453 Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds 20 1981
 
AKZO N.V. (1)
5324522 Sustained release thyroactive composition 25 1992
 
Rega Stichting v.z.w. (1)
5663159 Prodrugs of phosphonates 92 1994
 
Southern Arizona Veterans Affairs Health Care System (1)
6534676 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same 6 2001
 
MERCK SHARP & DOHME CORP. (1)
6680340 Anti-hypercholesterolemic drug combination 2 2003
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (1)
5571840 Method for treating central nervous system ischemia 25 1994
 
ALTERGON S.A. (SWISS JOINT STOCK COMPANY) (1)
2004/0219,218 Pharmaceutical formulae for thyroid hormones and procedures for obtaining them 3 2003
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (5)
6236946 Nuclear receptor ligands and ligand binding domains 5 1996
5883294 Selective thyroid hormone analogs 15 1997
6266622 Nuclear receptor ligands and ligand binding domains 4 1997
6107517 Thyroid hormone analogues and methods for their preparation 3 1999
6555582 Eye treatments using synthetic thyroid hormone compositions 5 1999
 
KOO, CATHERINE, DR (3)
6221911 Uses for thyroid hormone compounds or thyroid hormone-like compounds 19 1998
6380255 Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds 5 2000
2002/0123,521 Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds 4 2002
 
METABASIS THERAPEUTICS, INC. (2)
* 7514419 Phosphorus-containing thyromimetics 5 2005
2006/0046,980 Novel phosphorus-containing thyromimetics 9 2005
 
Ono Pharmaceutical Co., Ltd. (1)
* 6495533 Drugs containing phosphoric acid derivatives as the active ingredient 2 2001
 
BRISTOL-MYERS SQUIBB COMPANY (7)
6414002 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 57 2001
6727271 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 38 2002
6673815 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 45 2002
6831102 Phenyl naphthol ligands for thyroid hormone receptor 4 2002
6747048 Pyridine-based thyroid receptor ligands 4 2003
6875782 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method 16 2003
2005/0004,184 Thyroid receptor ligands 5 2004
 
NIPPON ZOKI PHARMACEUTICAL CO., LTD. (1)
5116828 Pharmaceutical composition for treatment of osteoporosis 40 1990
 
WARNER-LAMBERT COMPANY LLC (1)
6545150 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation 1 2001
 
Octamer, Inc. (1)
5922775 Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity 11 1997
 
Arthromics plc (1)
6414026 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease 10 2001
 
Smith Kline & French Laboratories Limited (4)
4766121 Pyridyl and pyridazinyl substituted thyronine compounds having selective thyromimetic activity 25 1986
4826876 Chemical compounds having selective thyromimetic activity 17 1987
4910305 Pyridyl and pyridazinyl substituted thyronine compounds 14 1988
5061798 Benzyl pyridyl and pyridazinyl compounds 19 1989
 
BAYER AKTIENGESELLSCHAFT (3)
6608049 Indazoles 6 2001
6794406 Indole derivatives 4 2001
7015246 Benzofuran derivatives 2 2002
 
BTG INTERNATIONAL INC. (1)
5158978 Thyroid hormone treatment of acute cardiovascular compromise 30 1991
 
REGENERON PHARMACEUTICALS, INC. (1)
2004/0142,868 Method of treating liver steatosis in a mammal 2 2004
 
MERCK & CO., INC. (1)
* 5519163 Inhibitors of phosphoinositide-specific phospholipase C 4 1993
 
LIGAND PHARMACEUTICALS INCORPORATED (1)
6566372 Bicyclic androgen and progesterone receptor modulator compounds and methods 40 2000
 
KARO BIO AB (4)
5854282 3-benzoyl benzofuran derivatives as thyroid hormone antagonists 11 1997
* 6465687 Thyroid receptor ligands and method 3 2000
6492424 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders 2 2001
6806381 Process for the preparation of aniline-derived thyroid receptor ligands 4 2002
 
BOEHRINGER MANNHEIM GMBH (1)
4423227 Process for the preparation of reactive, couplable derivatives of the thyroid hormones 3 1981
 
Shionogi & Co., Ltd. (1)
2003/0153,513 Preventives or remedies for obesity or fatty liver 3 2003
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
METABASIS THERAPEUTICS, INC. (1)
* 2010/0081,634 Novel Phosphorus-Containing Thyromimetics 1 2006
 
DOW GLOBAL TECHNOLOGIES LLC (4)
8201615 Heat storage devices 2 2009
* 8091613 Thermal energy storage materials 4 2009
* 2009/0250,189 HEAT STORAGE DEVICES 18 2009
8590598 Devices for storing and discharging heat and methods thereof 0 2012
 
LORD CORPORATION (2)
* 8859098 Acrylic adhesion promoters 0 2012
* 2013/0309,508 ACRYLIC ADHESION PROMOTERS 0 2012
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 9, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 9, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00